Risk of B-cell lymphoma in MPN patients treated with JAK1/2 inhibitors: Contradictory results?

Costanza, Mariangela; Spertini, Olivier; Blum, Sabine

Costanza, Mariangela; Spertini, Olivier; Blum, Sabine.

Afiliación

Costanza M; Service and Central Laboratory of Hematology, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. Electronic address: mariangela.costanza@chuv.ch.
Spertini O; Service and Central Laboratory of Hematology, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Blum S; Service and Central Laboratory of Hematology, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.

Leuk Res ; 90: 106313, 2020 03.

Article en En | MEDLINE | ID: mdl-32058175

Asunto(s)

Linfoma de Células B/epidemiología; Linfoma de Células B/etiología; Trastornos Mieloproliferativos/epidemiología; Susceptibilidad a Enfermedades; Humanos; Incidencia; Janus Quinasa 1/antagonistas & inhibidores; Janus Quinasa 2/antagonistas & inhibidores; Inhibidores de las Cinasas Janus/efectos adversos; Inhibidores de las Cinasas Janus/uso terapéutico; Terapia Molecular Dirigida/efectos adversos; Terapia Molecular Dirigida/métodos; Trastornos Mieloproliferativos/tratamiento farmacológico

Palabras clave

JAK1/2 inhibitors; Lymphoma; Myeloproliferative neoplasms

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma de Células B / Trastornos Mieloproliferativos Tipo de estudio: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Res Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google